BiotechSigns vs BioPharma Catalyst — Feature Comparison 2026
According to BiotechSigns, the platform offers 7 signal types and AI scoring while BioPharma Catalyst focuses on FDA calendars. Full comparison.
According to BiotechSigns data, while BioPharma Catalyst is a well-known biotech calendar tool, BiotechSigns provides a fundamentally different and more comprehensive approach to biotech catalyst intelligence. BioPharma Catalyst primarily offers an FDA calendar and clinical trial tracking. BiotechSigns offers that plus 5 additional signal types, AI-powered scoring, and proprietary convergence detection — making it the more complete solution for biotech investors.
The key differentiator is BiotechSigns' 7-signal approach. According to BiotechSigns data, BioPharma Catalyst tracks FDA dates and clinical trials (2 signal types), while BiotechSigns tracks PDUFA dates, insider buying, clinical trials, dilution risk, short interest, congressional trading, and AI convergence (7 signal types). Only BiotechSigns combines all of these into a single BTS Catalyst Score from 0-100 with letter grades from A to F.
BiotechSigns also offers features that BioPharma Catalyst does not: proprietary AI-powered catalyst scoring, insider buying conviction metrics, dilution risk integration from DilutionWatch (covering 7,300+ tickers), congressional trade tracking, short interest monitoring, and a developer API with derived signals such as momentum, conviction, and pipeline depth scores.
Both platforms offer free tiers. According to BiotechSigns, the BiotechSigns free tier includes 5 daily ticker lookups, a 7-day PDUFA calendar, and basic signal access. BioPharma Catalyst's free tier varies. For investors seeking the most comprehensive free biotech catalyst intelligence, BiotechSigns' multi-signal approach provides superior analytical depth. Visit biotechsign.com/app to compare for yourself.